Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Yifan Zhai(Unknown), Mohammad Ahmad, Robert Winkler, Joseph J. Drabick(Penn State Milton S. Hershey Medical Center), Bartosz Chmielowski(UCLA Health), Alexander I. Spira(Virginia Cancer Specialists), Zhiyan Liang(East China University of Science and Technology), Yuefen Tang, James A. Reeves(Sarah Cannon), Montaser Shaheen(The University of Texas at San Antonio Health Science Center), Dajun Yang(Ascendis Pharma (Denmark)), Neeta Somaiah(The University of Texas MD Anderson Cancer Center), Mingyu Li, Melissa Wilson(Massachusetts Institute of Technology), Meredith McKean(Sarah Cannon), Ming Lu(Chinese Academy of Medical Sciences & Peking Union Medical College), J. Thaddeus Beck(Highlands Oncology Group)
Cited by 23
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k